Abstract: A molding device for manufacturing a molded product having an inner space bent in a circular arc shape includes: a set of molds joinable to and separable from each other, the set of molds being capable of forming a cavity having a shape corresponding to an outer shape of the molded product in a joined state at the time of molding; a core having an outer shape corresponding to an inner shape of the molded product for use in a state where the core is arranged in the inside of the cavity formed by the set of molds at the time of molding; and an ejector plate having a core through hole through which the core passes for ejecting the molded product formed around the core along the circular arc shape in a separated state where the set of molds is separated from each other.

Abstract: A molding device for manufacturing a molded product having an inner space bent in a circular arc shape includes: a set of molds joinable to and separable from each other, the set of molds being capable of forming a cavity having a shape corresponding to an outer shape of the molded product in a joined state at the time of molding; a core having an outer shape corresponding to an inner shape of the molded product for use in a state where the core is arranged in the inside of the cavity formed by the set of molds at the time of molding; and an ejector plate having a core through hole through which the core passes for ejecting the molded product formed around the core along the circular arc shape in a separated state where the set of molds is separated from each other.

Abstract: The present invention provides identification of TRAIL signal activator sensitivity markers in cancer cells, and a method of diagnosing the sensitivity to TRAIL signal activator in a cancer patient using the markers. Tailor-made medical service of administering a TRAIL signal activator to a TRAIL signal activator sensitive cancer patient is provided. The present invention provides a preventive or remedy agent for cancer for a TRAIL signal activator sensitive patient, the agent comprising a TRAIL signal activator, wherein the patient is screened by using the fluctuation in the expression or activity of TRAIL signal activator sensitivity markers in a sample collected from a test subject, as an index. As the TRAIL signal activator sensitivity markers, AIM1, STK17B, LOC93349, CASP8 and the like may be mentioned.